

Patient safety

SGD Pharma's new range of Type I injectable vials in tubular glass, featuring Corning® Velocity® Vial coating technology and designed to optimize global fill & finish operations.

Velocity® is a registered trademark of Corning Incorporated

VELOCITY® VIALS:

Product features

Maximize productivity with better economics and better quality

An external low coefficient of friction (COF) coating helps to reduce friction created by glass-to-glass contact and glass-to-metal contact.

Velocity Vial's patented external coating can:





Improve fill & finish efficiency by 20-50%



Up to 96% reduction in glass particulates



Reduce the likelihood of damage that leads to cracks, breaks and cosmetic rejects

Wide range of sizes

SIZE	COLOR	ml	→ mm ≺	EE	NECK FINISH
2R	Clear & Amber	4	16	35	13
4R	Clear & Amber	6	16	45	13
6R	Clear & Amber	10	22	40	20
8R	Clear & Amber	11,5	22	45	20
10R	Clear & Amber	13,5	24	45	20
20R	Clear & Amber	26	30	55	20

Above you see the most frequently requested formats and configurations.

Other vial formats are available on request. Various configurations are available for bulk packaging.




VELOCITY® VIALS:

A friction-reducing and stabilizing outer coating

SGD Pharma's Velocity® Vial offering will consist of high-quality Type I borosilicate tubular glass with the added external low-friction coating developed by Corning, providing a solution with improved quality that makes the fill & finish process 50% more efficient by reducing the frictional resistance of the glass. Vials with a low friction coating exhibited a 3X reduction* in crack generation when subjected to simulated filling line damage compared with conventional pharmaceutical vials.

SGD Pharma's Type I tubular glass vials are already compliant with USP and EP requirements and are manufactured and released in accordance with ISO GMP standards. The Velocity® Vial coating technology is also compliant with EU and US health authorities and because the internal surface that comes into contact with the drug is not altered, there is no need for additional post-marketing drug approval processes.



^{*}Data based on Corning's study on Velocity® Vials

KEY PRODUCT BENEFITS







Thanks to an exclusive codevelopment partnership, SGD Pharma's vial-converting expertise is combined with Corning Incorporated's proprietary glass-coating technology. The collaboration will enhance vial quality, improve filling-line productivity, and speed the global delivery of injectable treatments



HIGH-QUALITY TYPE I TUBULAR VIALS WITH AN INNOVATIVE PROTECTIVE COATING

Improved performance for fill & finish

One of the key challenges for pharmaceutical filling lines is preventing potential disruptions to the flow of vials, which can include tip-overs, jams and glass breakages. Often issues such as these are caused by high frictional resistance from glass-to-glass and glass-to-metal contact. Defective vials force production lines to stop and can more critically result in expensive recalls and increased manufacturing costs.

To solve these production challenges, SGD Pharma has partnered with Corning Incorporated to co-manufacture Velocity® Vials in a new line at its Vemula, India glass production site, with Corning's innovative proprietary coating technology. This efficient new fill & finish offering will enhance vial quality, improve filling-line productivity, and speed up the global delivery of injectable and potentially life-saving treatments. The new joint venture will support drug manufacturers to respond to increasingly complex capacity and quality issues, while meeting global demand for critical medicines.

Improved Patient Safety

With the low COF Velocity® Vial coating, pharma filling units will see up to 96% reduction* in glass particulates. Hence there will be minimal chance of glass particulates getting trapped inside vials during fill & finish operations, protecting the end user and significantly improving product quality and safety.





SGD PHARMA

Corning and SGD Pharma are partnering in a joint venture to open new glass tubing facility and expand access to Corning[®] Velocity[®] Vial technology in India

SGD Pharma will manufacture Velocity® Vials at a new glass tubing facility located at its pre-existing Vemula, India production site.

On completion, this state-of-the-art facility will expand pharmaceutical packaging manufacturing in India and access to the Corning® Velocity® Vial technology in the region.

SGD Pharma Vemula currently specializes in Type I glass primary packaging for pharmaceutical and biotech applications with a best-in-class manufacturing footprint.

From design to manufacturing and delivery, SGD Pharma is committed to developing high quality products to meet worldwide pharmaceutical needs. The introduction of Velocity® Vials will contribute to the ongoing evolution of SGD Pharma's offerings and services and will expand its portfolio of high-quality glass packaging.





